文献速递白血病

维奈克拉联合多药化疗治疗初诊未明系列急性白血病患者的疗效与安全性分析

[Efficacy and safety analysis of venetoclax in combination with multidrug chemotherapy in patients with newly diagnosed acute leukemia of ambiguous lineage].
PubMed 文献 · Zhonghua Xue Ye Xue Za Zhi · 2025-01-01

该回顾性分析纳入2021年6月至2024年7月在江苏省人民医院住院的13例初诊未明系列急性白血病(ALAL)患者,均接受以维奈克拉为基础的联合多药化疗诱导治疗。13例患者均获完全缓解,中位总生存期未达到,75%位总生存期为12.0个月,12个月累积总生存率为64.5%;所有患者发生3级或4级血液学不良反应,无致死性大出血、肿瘤溶解综合征及3级及以上脏器不良反应。

要点

  • 13例初诊ALAL患者经维奈克拉联合多药化疗诱导后均获完全缓解。
  • 13例患者中位总生存期未达到,75%位总生存期为12.0个月,12个月累积总生存率为64.5%。
  • 所有患者发生3级或4级血液学不良反应,无致死性大出血及肿瘤溶解综合征。

核心结论

  • 维奈克拉联合多药化疗治疗初诊ALAL的疗效值得肯定,且治疗相关不良反应可耐受。

研究设计与样本

  • 回顾性分析2021年6月至2024年7月在江苏省人民医院住院治疗的13例初诊ALAL患者的临床资料。
  • 13例患者初始诱导治疗均为以维奈克拉为基础联合多药化疗,其中VAA+P方案治疗8例,V+IA方案治疗5例。
  • FLT3突变患者联合FLT3抑制剂,Ph(+)患者联合酪氨酸激酶抑制剂治疗。

主要发现

  • 根据WHO造血与淋巴组织肿瘤分类第五版,13例患者包括T/髓系混合表型急性白血病(MPAL)4例、B/髓系MPAL 7例、ALAL-非特指型2例。
  • 7例B/髓系MPAL患者中4例Ph(+),属ALAL特定的基因异常组别;3例患者存在FLT3突变(FLT3-TKD突变1例,FLT3-ITD突变2例)。
  • 巩固治疗前评估诱导疗效,13例患者均获完全缓解。
  • 巩固治疗中1例患者放弃治疗失访,9例进行异基因造血干细胞移植,其中4例因移植后并发症死亡、5例无病生存;3例年龄≥70岁患者按原方案巩固治疗,其中2例无病生存、1例因白血病中枢神经系统浸润死亡。
  • 13例患者中位总生存期未达到,75%位总生存期为12.0个月,12个月累积总生存率为64.5%;所有患者中位无病生存期未达到,75%位无病生存期为8.2个月,12个月累积无病生存率为67.1%。

关键数值与推荐

  • 13例患者经维奈克拉联合方案诱导治疗后完全缓解率为100%。
  • 13例患者中位总生存期未达到,75%位总生存期为12.0个月,12个月累积总生存率为64.5%。
  • 所有患者中位无病生存期未达到,75%位无病生存期为8.2个月,12个月累积无病生存率为67.1%。
  • 所有患者诱导治疗期间及治疗后均发生3级或4级血液学不良反应,包括中性粒细胞减少和血小板减少。
  • 所有患者经初始诱导治疗后造血功能恢复,无致死性大出血、肿瘤溶解综合征、神经系统不良反应及3级及以上脏器不良反应(患者治疗前基础病除外)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Objective: To evaluate the efficacy and safety of venetoclax in combination with multidrug chemotherapy in patients with newly diagnosed acute leukemia of ambiguous lineage (ALAL) . Methods: A retrospective analysis of clinical data was performed on patients with newly diagnosed ALAL who were hospitalized at Jiangsu Provincial People's Hospital from June 2021 to July 2024. Of the 13 patients who received initial induction therapy with venetoclax combined with multidrug chemotherapy, 8 received VAA+P regimen, and 5 received V+IA regimen. Patients with FLT3 mutation were treated with FLT3 inhibitor, and Ph(+) patients received an additional tyrosine kinase inhibitor. Overall survival (OS), disease-free survival (DFS), and adverse events were analyzed. Results: According to the World Health Organization 5th edition of the classification of hematolymphoid tumors, the immunophenotypes were T/myeloid mixed-phenotype acute leukemia (MPAL) (n=4), B/myeloid MPAL (n=7), and ALAL- not otherwise specified (n=2). Of the seven patients with B/myeloid MPAL, four were Ph(+) and belonged to the group with specific gene abnormalities of ALAL. Three patients had FLT3 mutation (one with FLT3-TKD mutation and two with FLT3-ITD mutation). Prior to the second course of consolidation therapy, the efficacy of venetoclax induction therapy was evaluated, and a complete response rate of 100% was achieved in 13 patients. In the subsequent consolidation therapy phase, one patient discontinued treatment and was lost to follow-up; nine patients underwent allogeneic hematopoietic stem cell transplantation, four of whom died due to posttransplant complications and five achieved DFS. Of the three patients (≥70 years old) who received consolidation therapy as before, two achieved DFS and one died due to central nervous system leukemia. The median OS time was not reached in 13 patients; the 75th percentile survival time was 12.0 months, with a 12-month cumulative survival rate of 64.5%. The median DFS time was not reached in all patients; the 75th percentile DFS time was 8.2 months, with a 12-month cumulative DFS rate of 67.1%. All patients experienced grade 3 or 4 hematologic toxicity, including neutropenia and thrombocytopenia, during and after induction therapy. All patients recovered hematopoietic function after the initial induction therapy, with no fatal hemorrhage, tumor lysis syndrome, neurological adverse events, or grade 3 or higher organ toxicity, excluding preexisting conditions. Conclusion: Venetoclax in combination with multidrug chemotherapy was effective and associated with tolerable adverse reactions in patients with newly diagnosed ALAL. 目的: 探讨维奈克拉(VEN)联合多药化疗治疗初诊未明系列急性白血病(ALAL)患者的疗效及安全性。 方法: 回顾性分析2021年6月至2024年7月在江苏省人民医院住院治疗的13例初诊ALAL患者的临床资料,13例患者的初始诱导治疗方案均为以VEN为基础联合多药化疗,其中VAA+P(VEN +阿扎胞苷/地西他滨+阿柔比星+醋酸泼尼松)方案治疗8例,V+IA(VEN +伊达比星+阿糖胞苷)方案治疗5例,FLT3突变患者联合FLT3抑制剂,Ph(+)患者联合酪氨酸激酶抑制剂治疗。分析患者的总生存(OS)期、无病生存(DFS)期及不良反应。 结果: 根据WHO造血与淋巴组织肿瘤分类第五版关于ALAL的免疫表型定义,13例ALAL患者包括T/髓系混合表型急性白血病(MPAL)4例,B/髓系MPAL 7例,ALAL-非特指型2例。其中4例B/髓系MPAL患者Ph(+),属ALAL特定的基因异常组别。3例患者存在FLT3突变(FLT3-TKD突变1例,FLT3-ITD突变2例)。于巩固治疗前评估VEN联合用药方案的诱导治疗效果:13例患者均获完全缓解(CR)。在随后的巩固治疗过程中,1例患者放弃治疗失访,9例患者进行异基因造血干细胞移植(allo-HSCT),其中4例因移植后并发症死亡,5例无病生存。3例患者(年龄≥70岁)按原方案巩固治疗,其中2例无病生存,1例因白血病中枢神经系统浸润死亡。13例患者的中位OS期未达到,75%位OS期为12.0个月,12个月累积OS率为64.5%,所有患者的中位DFS期未达到,75%位DFS期为8.2个月,12个月累积DFS率为67.1%。VEN联合方案诱导治疗期间及治疗后所有患者均发生3级或4级血液学不良反应,包括中性粒细胞减少和血小板减少。所有患者经初始诱导治疗后造血功能恢复且无致死性大出血发生;无患者出现肿瘤溶解综合征及神经系统不良反应;同时无3级及以上脏器不良反应发生(患者治疗前基础病除外)。 结论: VEN联合多药化疗治疗初诊ALAL的疗效值得肯定且治疗的相关不良反应可耐受。.

来源:Zhonghua Xue Ye Xue Za Zhi,查看原文。版权归原作者所有。

引用

  1. Luo T, Fang YR, Liu WJ, et al. [Efficacy and safety analysis of venetoclax in combination with multidrug chemotherapy in patients with newly diagnosed acute leukemia of ambiguous lineage]. Zhonghua Xue Ye Xue Za Zhi. 2025. PMID: 40134199. doi:10.3760/cma.j.cn121090-20240419-00149

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。